Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Gains from Investment Securities: 2019-2024

Historic Gains from Investment Securities for Cellebrite DI (CLBT) over the last 6 years, with Dec 2024 value amounting to $110.7 million.

  • Cellebrite DI's Gains from Investment Securities fell 93.43% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $414,000, marking a year-over-year decrease of 99.83%. This contributed to the annual value of $110.7 million for FY2024, which is 224.51% up from last year.
  • As of FY2024, Cellebrite DI's Gains from Investment Securities stood at $110.7 million, which was up 224.51% from $34.1 million recorded in FY2023.
  • In the past 5 years, Cellebrite DI's Gains from Investment Securities ranged from a high of $110.7 million in FY2024 and a low of -$36.5 million during FY2022.
  • Its 3-year average for Gains from Investment Securities is $36.1 million, with a median of $34.1 million in 2023.
  • As far as peak fluctuations go, Cellebrite DI's Gains from Investment Securities slumped by 511.10% in 2021, and later spiked by 224.51% in 2024.
  • Cellebrite DI's Gains from Investment Securities (Yearly) stood at $2.9 million in 2020, then slumped by 511.10% to -$12.0 million in 2021, then crashed by 204.70% to -$36.5 million in 2022, then skyrocketed by 193.52% to $34.1 million in 2023, then spiked by 224.51% to $110.7 million in 2024.